Greater Shepparton, Victoria, Australia – 10 June 2025: Akaal Pharma Pty Ltd (Akaal Pharma), a biopharmaceutical company focused on novel therapies for inflammatory and autoimmune skin disorders, today announced positive top-line results from its Phase 2 clinical trial. The multicenter, randomized, double-blind, placebo-controlled study evaluated its selective Sphingosine-1-Phosphate-receptor subtype-1 (S1P1) agonist, Takp-119, in patients with … Read more